These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 21761950)

  • 41. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
    Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
    Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.
    Cousins SJ; Radfar SR; Crèvecoeur-MacPhail D; Ang A; Darfler K; Rawson RA
    J Subst Abuse Treat; 2016 Apr; 63():66-71. PubMed ID: 26823295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia.
    Berger A; Sadosky A; Dukes EM; Edelsberg J; Zlateva G; Oster G
    Am J Manag Care; 2010 May; 16(5 Suppl):S126-37. PubMed ID: 20586521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Shanahan MD; Doran CM; Digiusto E; Bell J; Lintzeris N; White J; Ali R; Saunders JB; Mattick RP; Gilmour S
    Addict Behav; 2006 Mar; 31(3):371-87. PubMed ID: 15972245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Depressive symptomatology, medication persistence, and associated healthcare costs in older adults with glaucoma.
    Jayawant SS; Bhosle MJ; Anderson RT; Balkrishnan R
    J Glaucoma; 2007 Sep; 16(6):513-20. PubMed ID: 17873711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Peterson AN; Doyle J; Huse DM
    Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy.
    Han SH; Jing W; Mena E; Li M; Pinsky B; Tang H; Hebden T; Juday T
    J Med Econ; 2012; 15(6):1159-66. PubMed ID: 22780707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States.
    Asche CV; Clay E; Kharitonova E; Zah V; Ruby J; Aballéa S
    J Med Econ; 2015; 18(8):600-11. PubMed ID: 25851505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.
    Yu AP; Ben-Hamadi R; Wu EQ; Kaltenboeck A; Bergman R; Xie J; Blum S; Erder MH
    J Med Econ; 2011; 14(4):508-15. PubMed ID: 21692605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relapse prevention medications in community treatment for young adults with opioid addiction.
    Vo HT; Robbins E; Westwood M; Lezama D; Fishman M
    Subst Abus; 2016; 37(3):392-397. PubMed ID: 26820059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
    Greiner MG; Shulman M; Choo TH; Scodes J; Pavlicova M; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
    J Subst Abuse Treat; 2021 Dec; 131():108447. PubMed ID: 34098301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
    Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
    J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder.
    Zavod A; Akerman SC; Snow MM; Tierney M; Sullivan MA
    J Am Psychiatr Nurses Assoc; 2019; 25(4):272-279. PubMed ID: 30569814
    [No Abstract]   [Full Text] [Related]  

  • 59. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
    DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.